Discover What's New

Press Releases

Onset Dermatologics Launches HylatopicPlus® Cream 450 Gram Jar for Treating Eczema and Other Skin Conditions

Hylatopic® Becomes the Most Prescribed Skin Barrier Repair Therapy Brand
CUMBERLAND, R.I. (November 14, 2011) – Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the availability of HylatopicPlus Cream in a convenient 450 gram jar with pump dispenser. HylatopicPlus Cream is indicated to manage and relieve the burning, itching and pain experienced with various types of skin conditions, including atopic dermatitis (eczema), allergic contact dermatitis and radiation dermatitis. HylatopicPlus Cream also helps alleviate dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

Read More
Onset Dermatologics Launches HylatopicPlus® Cream For Treating Atopic Dermatitis and a Range of Other Skin Conditions

CUMBERLAND, R.I. (August 22, 2011)—Onset Dermatologics, a PreCision Dermatology company and a leader in developing and commercializing novel, prescription products for improving skin health, today announced the launch of HylatopicPlus® Cream. HylatopicPlus® Cream is indicated to manage and relieve the burning, itching and pain experienced with various types of skin conditions, including atopic dermatitis (eczema), allergic contact dermatitis and radiation dermatitis. HylatopicPlus® Cream also helps alleviate dry, waxy skin by maintaining a moist wound and skin environment, which is beneficial to the healing process.

Read More
New Data Confirm Clinical Efficacy and Strong Patient Preference for Onset Dermatologics Foam Products

CUMBERLAND, R.I., Feb. 8, 2011 (GLOBE NEWSWIRE) -- Onset Dermatologics, a PreCision Dermatology company and an emerging leader in the development and commercialization of novel, patent-protected products for the treatment of skin disorders, today announced that several clinical posters about Onset Dermatologics' products were presented during the Annual Meeting of the American Academy of Dermatology in New Orleans, LA from February 4th - 8th. Two of the studies validated the company's HylatopicPlus® Emollient Foam as an effective therapy for treating patients with atopic dermatitis and impaired skin barrier function. Two additional poster presentations confirmed the tolerability and patient preference for BenzEFoam® (benzoyl peroxide) Emollient Foam 5.3% for the treatment of acne.

Read More
Onset Therapeutics Changes Name to Onset Dermatologics

Cumberland, RI (February 4, 2011)—Onset Therapeutics, a PreCision Dermatology company and a leader in the development and commercialization of novel, prescription products for the treatment of skin disorders, today announced that it has changed its corporate name to Onset Dermatologics. The name change has been undertaken to emphasize the Company's focus on dermatology and on delivering advanced topical therapies that patients prefer. Onset Dermatologics will be exhibiting its full line of products at Booth # 2170 at the upcoming American Academy of Dermatology Annual Meeting taking place in New Orleans, LA from February 4th - 8th.

Read More
PreCision Dermatology Forms With Onset Therapeutics as Core Commercial and Technology Base

Cumberland, RI (December 1, 2010) — PreCision Dermatology Inc., a company focused on developing, manufacturing, acquiring and marketing a broad portfolio of innovative dermatology products, today announced it was formed as the result of the spin-out of Onset Therapeutics, a wholly owned subsidiary of Collegium Pharmaceutical, Inc. PreCision Dermatology also announced the close of a Series A financing led by life science private equity investor Essex Woodlands. Existing Collegium Pharmaceutical investors including Boston Millennia Partners, Frazier Healthcare and Westfield Capital Management also participated in the financing.

Read More